HDL/LDL Regulation
Cardiovascular Disease
Pre-clinicalActive
Key Facts
About Alpha-1 Biologics
Alpha-1 Biologics is a pre-clinical stage biotech leveraging foundational research from its founder, Dr. Cynthia L. Bristow, to develop oral therapies that modulate immune cell trafficking. The company's core technology aims to generate immune cells from stem cells within the body, targeting significant unmet needs in cancer immunotherapy and primary/secondary immunodeficiencies. It has been historically funded by non-profit research organizations but appears to be a private, early-stage venture with a pipeline yet to enter clinical trials. The leadership brings deep academic and clinical immunology expertise, though the company's operational scale and recent funding trajectory are not publicly detailed.
View full company profileTherapeutic Areas
Other Cardiovascular Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Manocept Diagnostic | Navidea Biopharmaceuticals | Research |
| Undisclosed Therapeutic Program(s) | HeartcoR Solutions | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Undisclosed Cardiovascular Device Program | Transluminal Technologies | Pre-clinical |
| iPSC-CM Cell Therapy | Khloris Biosciences | Research |
| Clinical Trial Integration | Aktiia | Various |
| Cardiovascular Disease Study | Arizona Research Center | Not Specified |
| Cardiovascular Clinical Trials | PanThera Bio | Not Specified |
| Undisclosed | Zecardio Therapeutics | Discovery/Pre-clinical |
| Cardiovascular Program | Helixomer | Research |
| Undisclosed Cardiovascular Program | inQB8 Medical Technologies | Pre-clinical |
| Undisclosed Cardiovascular Program(s) | Salubris Biotherapeutics | Clinical-stage (phase unspecified) |